PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) and 908 Devices (NASDAQ:MASS – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Risk and Volatility
PROCEPT BioRobotics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Valuation and Earnings
This table compares PROCEPT BioRobotics and 908 Devices”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PROCEPT BioRobotics | $224.50 million | 9.42 | -$91.41 million | ($1.55) | -24.52 |
| 908 Devices | $59.63 million | 3.62 | -$72.21 million | ($0.54) | -11.15 |
908 Devices has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares PROCEPT BioRobotics and 908 Devices’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PROCEPT BioRobotics | -30.60% | -23.73% | -17.34% |
| 908 Devices | -30.54% | -24.30% | -18.55% |
Insider and Institutional Ownership
89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 23.7% of 908 Devices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for PROCEPT BioRobotics and 908 Devices, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PROCEPT BioRobotics | 0 | 1 | 7 | 0 | 2.88 |
| 908 Devices | 0 | 0 | 3 | 1 | 3.25 |
PROCEPT BioRobotics currently has a consensus target price of $70.00, suggesting a potential upside of 84.21%. 908 Devices has a consensus target price of $8.00, suggesting a potential upside of 32.89%. Given PROCEPT BioRobotics’ higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than 908 Devices.
Summary
PROCEPT BioRobotics beats 908 Devices on 8 of the 15 factors compared between the two stocks.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
